List view / Grid view

Antibodies

 

Application note: A novel solution to expedite antibody discovery

29 November 2018 | By

With breakthroughs in molecular engineering and antibody humanisation, monoclonal antibodies (mAb) are one of the fastest-growing classes of biopharmaceuticals for multiple clinical indications including cancer, cardiovascular disease, autoimmune disorders and infectious disease. Most therapeutic antibody candidates are initially generated using hybridoma technology or primary B-cell screening after antigen immunisation.

ELRIG UK Drug Discovery 2018 Event

19 September 2018 | By

ELRIG’s (European Laboratory Research & Innovation Group) Drug Discovery meeting, will take place at ExCeL, London, UK, located in the heart of the city, from 9 -10 October 2018...

Expert view: Multiplexed screens in biologics discovery

7 September 2018 | By

Biologics are the fastest growing class of therapeutics in the biopharmaceutical industry. A key driver for this growth is success with anti-cancer immunotherapeutics such as checkpoint modulation, adoptive cell therapy and bispecific T-cell engagers. While these approaches use different tactics to attack tumours, they often employ monoclonal antibodies to target…

Antibodies In-Depth Focus 2018

6 September 2018 | By

In this In-Depth Focus, Stefan R. Schmidt discusses the current status and future perspectives of monoclonal antibodies and Tony Edge explains why the determination of aggregate is critical in the formation of monoclonal antibodies.

Expert view: Assays to measure the potency of therapeutic antibodies used in combination with other drugs for Immuno‑Oncology treatments

6 September 2018 | By

Growing evidence reveals that using single immunotherapies to treat oncological disorders may lead to cancer-killing T-cell overdrive,initiating life-threatening autoimmune reactions including cytokinestorm; also known as hypercytokinemia or Cytokine Release Syndrome(CRS). Recently, checkpoint blockade using anti-programmed cell death1 (anti-PD-1) inhibitors became a prevalent approach for stimulatinganti-tumour immune system.